Hypertension:高血压前期及高血压亚型均可预测心血管疾病风险

2012-05-06 高晓方译 医学论坛网

  亚洲学者的一项研究表明,在亚太地区,高血压前期以及包括单纯舒张期高血压在内的所有高血压亚型均可明确预测心血管疾病风险升高。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。   美国高血压防治指南JNC 7将血压处于120~139/80~89 mmHg定义为高血压前期,并将血压≥140/90 mmHg定义为高血压。高血压可分为单纯舒

  亚洲学者的一项研究表明,在亚太地区,高血压前期以及包括单纯舒张期高血压在内的所有高血压亚型均可明确预测心血管疾病风险升高。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。

  美国高血压防治指南JNC 7将血压处于120~139/80~89 mmHg定义为高血压前期,并将血压≥140/90 mmHg定义为高血压。高血压可分为单纯舒张期(IDH)、单纯收缩期和收缩-舒张期高血压。尽管有明确证据显示单纯收缩期和收缩-舒张期高血压可升高未来血管事件风险,但目前尚不清楚IDH的影响。此项研究从36项队列研究中纳入了346570例受试者。转归为致死性和非致死性心血管疾病(CVD)。对年龄、胆固醇和吸烟进行校正并对性别和研究进行分层后,利用Cox比例风险模型评估血压分类与CVD的相关性。

  结果显示,与正常血压相比,高血压前期、IDH、单纯收缩期高血压和收缩-舒张期高血压的CVD危险比分别为1.41、1.81、2.18和3.42。同时可观察到高血压前期和高血压亚型对冠心病、缺血性卒中和出血性卒中的显著独立影响。

  链接:

  Effects of Prehypertension and Hypertension Subtype on Cardiovascular Disease in the Asia-Pacific Region



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725420, encodeId=b8441e25420a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 25 03:18:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038442, encodeId=5157203844284, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 18 03:18:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472911, encodeId=704014e291158, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490834, encodeId=a0281490834c9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497746, encodeId=7d35149e7463a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500999, encodeId=cef115009996e, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
    2012-11-25 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725420, encodeId=b8441e25420a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 25 03:18:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038442, encodeId=5157203844284, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 18 03:18:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472911, encodeId=704014e291158, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490834, encodeId=a0281490834c9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497746, encodeId=7d35149e7463a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500999, encodeId=cef115009996e, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725420, encodeId=b8441e25420a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 25 03:18:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038442, encodeId=5157203844284, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 18 03:18:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472911, encodeId=704014e291158, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490834, encodeId=a0281490834c9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497746, encodeId=7d35149e7463a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500999, encodeId=cef115009996e, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725420, encodeId=b8441e25420a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 25 03:18:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038442, encodeId=5157203844284, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 18 03:18:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472911, encodeId=704014e291158, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490834, encodeId=a0281490834c9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497746, encodeId=7d35149e7463a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500999, encodeId=cef115009996e, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1725420, encodeId=b8441e25420a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 25 03:18:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038442, encodeId=5157203844284, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 18 03:18:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472911, encodeId=704014e291158, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490834, encodeId=a0281490834c9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497746, encodeId=7d35149e7463a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500999, encodeId=cef115009996e, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1725420, encodeId=b8441e25420a5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Nov 25 03:18:00 CST 2012, time=2012-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038442, encodeId=5157203844284, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Jun 18 03:18:00 CST 2012, time=2012-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472911, encodeId=704014e291158, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490834, encodeId=a0281490834c9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497746, encodeId=7d35149e7463a, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500999, encodeId=cef115009996e, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon May 07 15:18:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]

相关资讯

EHJ:荟萃分析显示降低高血压死亡率ACEI优于ARBs

       Laura C van Vark博士(荷兰伊拉斯姆斯大学医学中心)和他的同事在他们发表于2012年4月17日《欧洲心脏病杂志》[European heart journal.2012-04-17.]的一项新的荟萃分析表明,与同一时期的应用非ACEI类药物或血管紧张素受体阻滞剂等药物(ARBs)的患者相比应用ACEI类药物的高血压患者的全死因死亡

FDA更新含阿利吉仑降压药安全性标签

  4月20日,美国食品与药物管理局(FDA)发布公告称,若将含阿利吉仑的抗高血压药与血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体阻滞剂(ARB)联用,则糖尿病及有中重度肾损伤患者具有发生肾损伤、低血压及高钾血症的风险,因此应避免使用。但在未咨询医师的情况下,正在接受含阿利吉仑药物治疗的患者不应擅自停用该类药物。   须修改安全性标签的药物有:① Amturnide(阿利吉仑/

高血压增加TN风险

  三叉神经痛(TN)是一种于面部三叉神经分布区内反复发作的阵发性剧烈神经痛,多于40岁以后起病,女性多于男性,右侧多于左侧,呈现周期性发作。在临床上,通常将其分为原发性和继发性两种。原发性TN病因不清, 继发性TN常继发于局部感染、外伤、三叉神经所通过的骨孔狭窄、肿瘤、血管畸形和血液循环障碍等。   本期华夏医药栏目选取TN相关研究及外科治疗进展文章进行介绍,并由上海武警总医院潘绵顺

糖尿病高血压是老年动脉僵硬度增高的影响因素

  近日,北京大学第三医院老年内科刘喆、王海宁、王峥嵘等人共同发表论文,旨在评价老年高血压和(或)糖尿病患者动脉僵硬度及其影响因素。研究指出,糖尿病、高血压是老年人动脉僵硬度增高的影响因素,而高血糖对老年人动脉僵硬度的影响可能起了更重要的作用。血糖、平均动脉压、脉压、超每C反应蛋白、低密度脂蛋白胆固醇均是影响动脉僵硬度的独立危险因素。该文发表在2012年第31卷第1期《中华老年医学杂志》上。  

宁光教授等出席CODHy拉丁美洲会议并组织中国专场

  3月22日~25日,糖尿病、肥胖与高血压争议到共识会议(CODHy)拉丁美洲会议在巴西里约热内卢召开,集中讨论了糖尿病、肥胖和高血压领域最具争议的话题。   中华医学会内分泌学分会主任委员宁光教授与众多中国内分泌学专家出席了本次会议并组织“中国之声(Voice of China)”专场,就“传统中药在2型糖尿病治疗领域的研究进展”、&ldquo

噻嗪类利尿剂存在显著效力差异

  英国学者的一项荟萃分析表明,氢氯噻嗪、氯噻酮和苄氟噻嗪在效力方面存在显著差异,这可能解释了标准剂量氢氯噻嗪和氯噻酮的降压效果差异。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。   噻嗪类和噻嗪样利尿剂被广泛用于高血压治疗,但近来对氢氯噻嗪和氯噻酮在降压和心血管疾病预防方面的等效性有所质疑。此项研究对3种广泛应用噻嗪类利尿剂(氢氯噻嗪、氯噻酮和苄氟噻嗪)与血